Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043368 · ClinicalTrials.gov registry record · Phase 2
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
A Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 20
- Study locations
NCT00043368: Completed Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
NCT00043368 is a Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 31 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043368, a Phase 2 study of Melanoma and Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 20
- Study locations
Study Summary
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
Conditions Studied
Interventions
- DRUG PF-3512676
Study Locations (20)
Florida
- Pfizer Investigational Site - Bonita Springs
- Pfizer Investigational Site - Bradenton
- Pfizer Investigational Site - Cape Coral
- Pfizer Investigational Site - Fort Myers
- Pfizer Investigational Site - Fort Myers
- Pfizer Investigational Site - Naples
- Pfizer Investigational Site - Plantation
- Pfizer Investigational Site - Port Charlotte
- Pfizer Investigational Site - Sarasota
- Pfizer Investigational Site - Venice
- Pfizer Investigational Site - Venice
California
- Pfizer Investigational Site - Berkely
- Pfizer Investigational Site - Gilroy
- Pfizer Investigational Site - Hollister
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Palm Springs
- Pfizer Investigational Site - Stanford
Connecticut
- Pfizer Investigational Site - New Haven
Illinois
- Pfizer Investigational Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00043368 record still lists
NCT00043368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which PF-3512676 is the first listed.
NCT00043368 names 20 study sites across 4 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00043368 about?
NCT00043368 is a clinical study titled "PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)". This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
What is the current status of trial NCT00043368?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2002-09. Estimated completion is 2007-06.
What conditions does trial NCT00043368 study?
This clinical trial studies the following conditions: Melanoma, Carcinoma, Non-Small Cell Lung, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell.
What interventions are being tested in trial NCT00043368?
The interventions under investigation include: PF-3512676 (DRUG).
Who is sponsoring clinical trial NCT00043368?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043368 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00043368's enrollment target sits among peer trials
31 196th of 266 higher than 71 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia